ArticleIranian journal of pathology2026
Association between Serum Ferritin level and Liver Fibrosis Severity in Non-Alcoholic Fatty Liver Disease Patients.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by hepatic fat accumulation, which can progress fibrosis and cirrhosis. Serum ferritin has been proposed as a biomarker for liver disease, but its relationship with fibrosis severity in NAFLD remains unclear. This study explored the relationship between serum ferritin levels and liver fibrosis severity in NAFLD patients. Methods: In this cross-sectional study, 204 NAFLD patients were enrolled, including 139 with mild fibrosis and 65 with severe fibrosis. Baseline and demographic characteristics were compared between groups. Serum ferritin and other biochemical parameters were measured. Logistic regression analyses assessed the predictive value of serum ferritin levels for liver fibrosis severity, and a receiver operating characteristic (ROC) curve determined the optimal ferritin cutoff for identifying sever fibrosis. Results: Patients with severe fibrosis had significantly higher serum ferritin levels than those with mild fibrosis (197.70 ± 79.40 vs 95.70 ± 73.20, P<0.001). Logistic regression analysis confirmed a significant association between ferritin levels and fibrosis severity (OR = 1.015, 95% CI = 1.009-1.02, P<0.001). ROC analysis showed that ferritin distinguished severe from mild fibrosis with 80% sensitivity and 80% specificity at a cutoff of 129 ng/ml (AUC = 0.86). Conclusion: Elevated serum ferritin levels are associated with more severe liver fibrosis in NAFLD patients, supporting ferritin's potential as a non-invasive biomarker for fibrosis severity. Further studies are needed to validate these findings and explore ferritin's diagnostic and prognostic utility in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.